Format

Send to

Choose Destination
Lupus. 2018 Nov;27(13):2029-2040. doi: 10.1177/0961203318804885. Epub 2018 Oct 9.

Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus.

Author information

1
1 Centre for Inflammatory Diseases, Monash University School of Clinical Sciences at Monash Health, Melbourne, Victoria, Australia.
2
2 Department of Nephrology, Monash Health, and Monash University, Clayton, Victoria, Australia.
3
3 Western Health, Department of Nephrology, St Albans, Victoria, Australia.
4
4 The Department of Medicine, Western Health, The University of Melbourne, St Albans, Victoria, Australia.
5
5 National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
6
6 The Renal Unit, The Alfred Hospital, Prahran, Victoria, Australia.
7
7 Department of Immunology and Pathology, Monash University, Central Clinical School, Melbourne, Victoria, Australia.
8
8 Rheumatology Department, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
9
9 Department of Microbiology and Immunology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.

Abstract

INTRODUCTION:

We examined the clinical relevance of urinary concentrations of B-cell-activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE).

METHODS:

We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000.

RESULTS:

uBAFF was detected in 12% (10/85) of SLE patients, but was undetectable in HCs, IgAN and pSS patients. uBAFF was detectable in 28% (5/18) of SLE patients with active nephritis vs 5/67 (7%) of those without ( p = 0.03), and uBAFF was significantly higher in active renal patients ( p = 0.02) and more likely to be detected in patients with persistently active renal disease. In comparison, uAPRIL and uMCP-1 were detected in 32% (25/77) and 46% (22/48) of SLE patients, respectively. While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease.

CONCLUSIONS:

uBAFF was detectable in a small but a significant proportion of SLE patients but not in other groups tested, and was higher in SLE patients with active renal disease.

KEYWORDS:

A proliferation-inducing ligand (APRIL); B-cell–activating factor from the tumour necrosis factor family (BAFF); biomarker; lupus nephritis (LN); monocyte chemoattractant protein 1 (MCP-1); systemic lupus erythematosus (SLE)

PMID:
30301439
DOI:
10.1177/0961203318804885
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center